• Sign Up

Use coupon code EXTENDEDHOLIDAY2020 at checkout for 20% off

Pancreatic Mucinous Cystadenoma


Pancreatic Mucinous Cystadenoma

Article Author:
Srinivas Bojanapu
Article Editor:
Anup Kasi
Updated:
11/24/2020 10:58:17 AM
For CME on this topic:
Pancreatic Mucinous Cystadenoma CME
PubMed Link:
Pancreatic Mucinous Cystadenoma

Introduction

Mucinous cystadenoma (MCN) is an epithelial neoplasm producing mucin and forming cysts arising from the pancreas. They account for nearly half of cystic neoplasms of the pancreas, with the others being serous cystadenoma (SCN) and intraductal papillary mucinous neoplasm (IPMN). MCNs and IPMN have features in common like cyst formation, mucin production, and progressing to invasive carcinoma. Most often, MCNs are located in the body and tail region of the pancreas, and they are often found incidentally.[1] MCNs are noticed most frequently in females, and they usually present in a young woman without any previous history or risk factor for pancreatitis. Investigations preferably include magnetic resonance imaging or contrast-enhanced computed tomography supplemented by endoscopic ultrasound with cyst fluid aspiration. MCNs are premalignant neoplasms and surgical excision is preferred. A completely excised cyst that has no features of carcinoma rarely recur and do not warrant a regular follow up.[2]

Etiology

The exact origin of this neoplasm is still debated, with immunophenotype resembling ovarian type stroma. Research suggests the etiology may be stimulation by female hormones of immature endodermal stroma or implantation of primary yolk cells in the pancreas.[3][4] The most common and early genetic alteration occurring in MCN is the KRAS gene. SMAD4 and TP53 alterations are seen in invasive or high-grade lesions.

Epidemiology

MCNs are rare when compared to pseudocysts and pancreatic ductal adenocarcinoma, with few studies reporting on epidemiology. Reportedly MCNs account for 29% of neoplastic cystic lesions of the pancreas. Predominantly MCNs are seen in females, and the mean age of diagnosis is between 40 to 50 years (range 4 to 95 years).[5][6] Virtually all MCNs occur in women, and it is rare to find these lesions in men. The majority of MCNs are found in the body and tail region of the pancreas.[5][7][8]

Pathophysiology

MCNs are well-encapsulated and usually large-ranging up to 25 cm. The origin is from the pancreatic ductal cell. MCNs can present as a spectrum from a benign to borderline and frankly malignant lesions. They are usually slow-growing. MCNs lacking features of malignancy are considered to be premalignant[9]

Histopathology

MCNs are characterized by mucin-producing, cystic epithelial neoplasms with septations. Fluid in the cyst when aspirated, is usually thick and viscous. The cysts are lined by columnar epithelium, which may occur in a single layer with some areas showing papillary projections or invaginations. The presence of ovarian stroma is the pathognomonic finding in an MCN.  FNA cytology shows characteristic honeycomb sheets, with mucin-producing columnar cells in clusters and rich in mucin. MCNs do not communicate with the pancreatic ductal system, which is the fundamental differentiating character from IPMNs.[4][10] They usually occur solitarily.[4]

History and Physical

A combination of history and imaging increases diagnostic accuracy. Detailed information to rule out pancreatitis is of utmost importance since MCNs can present with abdominal pain, recurrent pancreatitis, gastric outlet obstruction, jaundice, or weight loss. However, cystic neoplasms, by and large, are diagnosed incidentally.[8] The examination may reveal a lump in the upper abdomen in an occasional patient.

Evaluation

Imaging

Imaging plays a crucial role in diagnosing MCNs. Imaging is done to determine the specific cyst type and to establish features of malignant transformation.

1. Transcutaneous ultrasound may be useful occasionally, but a deep-seated pancreas is not always visualized in entirety.

2. Magnetic resonance cholangiopancreatography (MRCP) is preferred to CT where available, as it is more sensitive for demonstrating ductal communication and internal architecture. A contrast-enhanced CT (pancreatic protocol) can also provide information and typically shows a septated cystic lesion or rarely a unilocular lesion as an initial assessment.

Typically, on MRI, MCNs appear as oligocellular, micro, or macrocytic and occupying the body and tail region of the pancreas. Since MCNs contain fluid in their cystic cavities, T2-weighted images are hyperintense. MRI also demonstrates if any ductal communication exists. 

Features suggesting malignant transformation include:[8][11][12]

  1. Thickened wall
  2. Internal solid component or mass
  3. Possible calcification of the cyst wall.

3. Endoscopic ultrasound (EUS) gives a better evaluation of the cyst wall and evaluates for any nodules. EUS can also be used for aspirating cyst fluid for analysis. Suspicious features include diameter >3 cm, mural nodules, thick and irregular walls, and an obstructed pancreatic duct.

4. The role of F-18 FDG positron-emission tomography is still not defined in MCNs and is still being investigated. 

Cystic Fluid

1. Fluid CEA levels >192 ng/mL has up to 79% accuracy in differentiating mucinous from non-mucinous cystic neoplasms.[13] A high CEA in the cyst fluid also suggests malignancy. 

2. Aspirated fluid from the cyst has to be sent for cytology to evaluate for the presence of dysplasia or cancer, more so when imaging features are inconclusive.

Treatment / Management

1. MCNs have a substantial risk for malignancy. Treatment of MCNs is surgical resection.[14] Resection is recommended in a patient with the following findings:

  1. Symptomatic MCNs irrespective of size
  2. MCNs of size > 4.0 cm
  3. MCNs with suspicious features irrespective of size 

If there is no suspicion of carcinoma, a spleen preserving or parenchyma sparing procedure (non-oncologic resection) can be performed. Minimally invasive procedures involving laparoscopic and robotic distal pancreatectomies are equally acceptable with similar oncologic outcomes and with the benefits of laparoscopy.[2][15][2][16]

MCNs with suspicious features should undergo standard oncologic resection which mostly involves distal pancreatico-splenectomy and lymph node dissection.

For asymptomatic MCNs of 3 to 4 cm treatment has to be individualized considering the patient's age, surgical risk, and patient's preference. Since determining the nature of a <3cm cystic lesion is difficult, the recommendation is for surveillance.

2. Surveillance recommendations include MRI, EUS, or a combination of both, every 6 months during the first year. If no changes are noted then imaging can be done annually during their lifetime as long as they are deemed fit to undergo surgery.

The American College of Gastroenterology guidelines suggest an imaging schedule based on the size of the cyst.[15]

  • <1 cm - MRI in 2 years.
  • 1-2 cm - MRI in 1 year.
  • 2-3 cm - MRI or EUS in 6 to 12 months

During surveillance, if a patient develops jaundice, acute pancreatitis, elevated serum CA19-9, mural nodules, or an increase in the size of the lesion they will need EUS with FNA and multidisciplinary panel referral.[15]

3. Cyst ablation with ethanol or paclitaxel injection and radiofrequency ablation has been studied but is not the standard of care at present.[15]

In summary, the patient's risk of developing a malignancy needs to be assessed against the risks of undergoing surgery. 

Differential Diagnosis

The most important differential diagnosis for MCNs are other cystic lesions of the pancreas

  • Intraductal papillary mucinous neoplasm (IPMN)
  • Serous cystadenoma
  • Pancreatic pseudocyst
  • Solid pseudopapillary tumor
  • Retention cyst
  • Simple mucinous cyst

Prognosis

After complete resection and in the absence of any invasive component on histopathological examination, the prognosis is excellent with an overall survival rate of 100%, and patients usually do not need any follow up.[8][17][17]

Complications

Morbidity of up to 50% is reported in various studies of which postoperative pancreatic fistulae are bothersome and require prolonged drainage. Though most fistulae are managed with intraoperatively placed drains, if they persist beyond 14 days, then endoscopic retrograde pancreaticography would be diagnostic, and a stent can be placed to decrease the drain output.[18]

Other complications include hemorrhage, which may require an interventional radiology consult or surgical intervention depending on the severity of the bleed.

Up to 20% of patients may be expected to develop new-onset diabetes mellitus after distal pancreatectomy and up to 10% in patients undergoing pancreaticoduodenectomy.

Deterrence and Patient Education

Patients undergoing resection for an MCN constituting a distal pancreatectomy or pancreaticoduodenectomy may develop diabetes mellitus by up to 20%. The patients need to be made aware and educated. Though having a resection for a confirmed benign lesion is unlikely to recur and do not mandate a followup. Whereas patients undergoing surgery for lesions with suspicious characteristics need regular followup with imaging.

Pearls and Other Issues

Cystic neoplasms of the pancreas have undergone extensive research and have now been classified into well-defined categories, with recommended management strategies. 

A middle-aged woman with a cystic lesion in the body and tail region of the pancreas very likely has a mucinous cystic lesion of the pancreas.

Enhancing Healthcare Team Outcomes

Mucinous cystadenoma, though uncommon, constitutes about 27% of cystic neoplasms of the pancreas. A detailed evaluation with CT and/or MRI abdomen and discussion with the radiologist to rule out suspicious features is pertinent to plan surgical strategy. When imaging is inconclusive, a gastroenterologist may be involved to perform endoscopic ultrasound (EUS) to characterize the cyst and its relation to the vessels. EUS can also be used simultaneously for the aspiration of cyst fluid to be sent for analysis. Since the condition is more often seen in a comparably younger age group, most patients are fit to undergo surgery. However, a pre-anesthetic check-up is needed to assess the patient's fitness for surgery. Post-surgery patients need to be started on prophylactic thromboprophylaxis. The patient also needs to be started on a spirometer, and physiotherapy for early ambulation is to be carried out.

Drains kept intra-operatively should be diligently monitored, for the quantity and character of the fluid. If this is high, drain fluid amylase needs to be obtained. If the patient has a pancreatic fistula, then the drain is to be kept for a longer duration until the output decreases to less than 30-50 ml. The patient may be discharged with the drain in place if the output is high and the patient is tolerating oral diet. Further follow-up and care by the supportive staff will be needed in this case.


References

[1] Compagno J,Oertel JE, Mucinous cystic neoplasms of the pancreas with overt and latent malignancy (cystadenocarcinoma and cystadenoma). A clinicopathologic study of 41 cases. American journal of clinical pathology. 1978 Jun;     [PubMed PMID: 665578]
[2] Tanaka M,Chari S,Adsay V,Fernandez-del Castillo C,Falconi M,Shimizu M,Yamaguchi K,Yamao K,Matsuno S, International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]. 2006;     [PubMed PMID: 16327281]
[3] Wenig BM,Albores-Saavedra J,Buetow PC,Heffess CS, Pancreatic mucinous cystic neoplasm with sarcomatous stroma: a report of three cases. The American journal of surgical pathology. 1997 Jan;     [PubMed PMID: 8990143]
[4] Zamboni G,Scarpa A,Bogina G,Iacono C,Bassi C,Talamini G,Sessa F,Capella C,Solcia E,Rickaert F,Mariuzzi GM,Klöppel G, Mucinous cystic tumors of the pancreas: clinicopathological features, prognosis, and relationship to other mucinous cystic tumors. The American journal of surgical pathology. 1999 Apr;     [PubMed PMID: 10199470]
[5] Le Borgne J,de Calan L,Partensky C, Cystadenomas and cystadenocarcinomas of the pancreas: a multiinstitutional retrospective study of 398 cases. French Surgical Association. Annals of surgery. 1999 Aug;     [PubMed PMID: 10450728]
[6] Garcea G,Ong SL,Rajesh A,Neal CP,Pollard CA,Berry DP,Dennison AR, Cystic lesions of the pancreas. A diagnostic and management dilemma. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]. 2008;     [PubMed PMID: 18497542]
[7] Fernández-del Castillo C,Warshaw AL, Cystic tumors of the pancreas. The Surgical clinics of North America. 1995 Oct;     [PubMed PMID: 7660245]
[8] Reddy RP,Smyrk TC,Zapiach M,Levy MJ,Pearson RK,Clain JE,Farnell MB,Sarr MG,Chari ST, Pancreatic mucinous cystic neoplasm defined by ovarian stroma: demographics, clinical features, and prevalence of cancer. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2004 Nov;     [PubMed PMID: 15551256]
[9] Sarr MG,Carpenter HA,Prabhakar LP,Orchard TF,Hughes S,van Heerden JA,DiMagno EP, Clinical and pathologic correlation of 84 mucinous cystic neoplasms of the pancreas: can one reliably differentiate benign from malignant (or premalignant) neoplasms? Annals of surgery. 2000 Feb;     [PubMed PMID: 10674612]
[10] Testini M,Gurrado A,Lissidini G,Venezia P,Greco L,Piccinni G, Management of mucinous cystic neoplasms of the pancreas. World journal of gastroenterology. 2010 Dec 7;     [PubMed PMID: 21128317]
[11] Gress F,Gottlieb K,Cummings O,Sherman S,Lehman G, Endoscopic ultrasound characteristics of mucinous cystic neoplasms of the pancreas. The American journal of gastroenterology. 2000 Apr;     [PubMed PMID: 10763945]
[12] Waters JA,Schmidt CM,Pinchot JW,White PB,Cummings OW,Pitt HA,Sandrasegaran K,Akisik F,Howard TJ,Nakeeb A,Zyromski NJ,Lillemoe KD, CT vs MRCP: optimal classification of IPMN type and extent. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. 2008 Jan;     [PubMed PMID: 17917784]
[13] Brugge WR,Lewandrowski K,Lee-Lewandrowski E,Centeno BA,Szydlo T,Regan S,del Castillo CF,Warshaw AL, Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. Gastroenterology. 2004 May;     [PubMed PMID: 15131794]
[14] European evidence-based guidelines on pancreatic cystic neoplasms. Gut. 2018 May;     [PubMed PMID: 29574408]
[15] Elta GH,Enestvedt BK,Sauer BG,Lennon AM, ACG Clinical Guideline: Diagnosis and Management of Pancreatic Cysts. The American journal of gastroenterology. 2018 Apr     [PubMed PMID: 29485131]
[16] Lee SY,Allen PJ,Sadot E,D'Angelica MI,DeMatteo RP,Fong Y,Jarnagin WR,Kingham TP, Distal pancreatectomy: a single institution's experience in open, laparoscopic, and robotic approaches. Journal of the American College of Surgeons. 2015 Jan;     [PubMed PMID: 25456783]
[17] Wilentz RE,Albores-Saavedra J,Zahurak M,Talamini MA,Yeo CJ,Cameron JL,Hruban RH, Pathologic examination accurately predicts prognosis in mucinous cystic neoplasms of the pancreas. The American journal of surgical pathology. 1999 Nov;     [PubMed PMID: 10555000]
[18] Hackert T,Werner J,Büchler MW, Postoperative pancreatic fistula. The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland. 2011 Aug;     [PubMed PMID: 21672661]